Marché mondial des vaccins contre le rotavirus humain – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse et taille du marché du vaccin contre le rotavirus humain

Les principaux facteurs qui devraient stimuler la croissance du marché des vaccins antirotavirus humains au cours de la période de prévision sont l’augmentation du développement, la hausse du nombre de personnes immunodéprimées et l’augmentation de la vigilance parmi la population. En outre, l’augmentation de la population âgée et l’augmentation de la population générale et des naissances vivantes sont deux facteurs qui propulsent davantage la croissance du marché des vaccins antirotavirus humains.

Selon Data Bridge Market Research, le marché mondial des vaccins contre le rotavirus humain, qui était de 7,20 milliards USD en 2022, devrait grimper à 10,36 milliards USD d'ici 2030 et devrait connaître un TCAC de 6,2 % au cours de la période de prévision 2023 à 2030. Cela indique la valeur du marché. « Rotarix » domine le segment type du marché mondial des vaccins contre le rotavirus humain en raison de l'augmentation du nombre de personnes souffrant de maladies virales. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également des analyses approfondies d'experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché des vaccins contre le rotavirus humain

Définition du marché

The Rotavirus vaccine is applied to prevent rotavirus infections which can cause severe diarrhea among young children. Symptoms of rotavirus infection consist of severe diarrhea, vomiting, fever, and abdominal pain, which can cause the disease. The Rotavirus vaccine is given by mouth and requires two or three doses starting around six weeks of age.

Global Human Rotavirus Vaccine Market Dynamics  

Drivers

Advancements in Vaccine Discovery and Manufacturing

Due to advancements in vaccine discovery and manufacturing, the Human Rotavirus Vaccine Market is quickly growing. Furthermore, the market expansion is being fueled by the growing geriatric population as well as raising public awareness.

Increased Vaccine Production

The Human Rotavirus Vaccine Market is expanding due to increased vaccine production. Rotavirus immunization protects children against rotavirus infections, which cause diarrhea. Severe diarrhea, vomiting, fever, and abdominal pain are all indications of rotavirus infection, which can lead to illness. Beginning about the age of six weeks, rotavirus vaccination is given orally in two or three doses.

Opportunities

Increase in Incidences of Human Rotavirus Infection

This increase in incidences is expected to drive the Human Rotavirus Vaccine Market during the forecast period, according to estimates. Various organizations, including UNICEF and GAVI, have urged for the use of the rotavirus vaccine in various countries to enhance immunization coverage and deliver immunizations at a lower cost, hence reducing illness instances and promoting a healthy lifestyle.   

Restraints/Challenges

High cost of vaccines:

The rise in vaccination prices and the vaccine’s unpleasant reactions and side effects would all stymie the market’s growth soon. The potential of bioterrorism and strict regulatory standards for the approval of novel human rotavirus vaccines are the main hindrance to the market.

Recent Development

• In 2017, the Serum Institute of India Pvt. Ltd. revealed the result of a clinical trial Phase 3 efficacy study of the rotavirus vaccine BRV-PV, ROTASIIL. The study has shown that the vaccine is safe, well tolerated, and provides significant efficacy against severe rotavirus gastroenteritis  

Global Human Rotavirus Vaccine Market Scope

The global human rotavirus vaccine market is segmented on the basis of type, application and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Rotarix
• Rotateq
• Rotavac
• Rotavin-M1
• Lanzhou Lamb
• Others

Application

• Hospitals and Clinics
• Academic and Research

End User

• Hospitals and Clinics
• Academic and Research
• Others

Global Human Rotavirus Vaccine Market Regional Analysis/Insights

The global human rotavirus vaccine market is analyzed and market size insights and trends are provided by country, type, application and end user, as referenced above.    

The countries covered in the global human rotavirus vaccine market report are the U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa.     

North America is expected to dominate the global human rotavirus vaccine market because of the strong base of healthcare facilities, the strong presence of major players in the market, increasing cases of viral infections and rising number of research activities in this region.      

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, growing research activities in the region, availability of massive untapped markets, a large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global human rotavirus vaccine market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global human rotavirus vaccine market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the global human rotavirus vaccine market. The data is available for the historic period 2015-2020.       

Competitive Landscape and Global Human Rotavirus Vaccine Market Share Analysis

Le paysage concurrentiel du marché mondial des vaccins contre le rotavirus humain fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises par rapport au marché.     

Certains des principaux acteurs opérant sur le marché mondial des vaccins contre le rotavirus humain sont :  

• Merck & Co., Inc. (États-Unis),
• Bharat Biotech (Inde),
• GlaxoSmithKline plc. (Royaume-Uni),
• Sanofi (France),
• Lanzhou Institute of Biologicals Products Co., Ltd (Chine),
• BIOVIRx Inc (États-Unis),
• Serum Institute of India Pvt. Ltd. (Inde),
• Biologique E (Inde),
• Bio Farma (Indonésie),
• Novartis SA (Suisse),
• Institut de recherche médicale Berghofer (Australie),
• Pfizer, Inc (États-Unis)

SKU-13241